Business & Finance Roundup: MusclePharm, ChromaDex, KonaRed And VDF
This article was originally published in The Tan Sheet
Executive Summary
MusclePharm wants out of manufacturing space; ChromaDex ingredient In NIH study and NDI from FDA; and KonaRed, VDF expand collaboration.
You may also be interested in...
Anti-Aging Supplement Moves Step Closer To EU Launch With EFSA Approval
ChromaDex' dietary supplement Niagen, marketed to help US consumers "age better", has taken a step closer to EU launch with a positive opinion by the European Food Safety Authority.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.